Open | - |
Close | - |
Volume / Avg. | 11.000 / 4.633M |
Day Range | - - - |
52 Wk Range | 0.920 - 3.789 |
Market Cap | $615.592M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 52 |
Short Interest | 15.7% |
Days to Cover | 4.06 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) through any online brokerage.
Other companies in Lexicon Pharmaceuticals’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Fate Therapeutics (NASDAQ:FATE), AnaptysBio (NASDAQ:ANAB) and Cullinan Oncology (NASDAQ:CGEM).
The latest price target for Lexicon Pharmaceuticals (NASDAQ: LXRX) was reported by Citigroup on Wednesday, May 31, 2023. The analyst firm set a price target for 8.00 expecting LXRX to rise to within 12 months (a possible 220.00% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Lexicon Pharmaceuticals (NASDAQ: LXRX) is $2.5 last updated March 18, 2024 at 6:44 PM EDT.
There are no upcoming dividends for Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals’s Q1 earnings are confirmed for Tuesday, April 30, 2024.
There is no upcoming split for Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.